These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Deep Alanine Scanning Reveals Potent Multi-alanine-substituted Protein–protein Interaction Inhibitors

submitted on 19.01.2021, 21:12 and posted on 21.01.2021, 04:46 by Xiyun Ye, Yen-Chun Lee, Zachary P. Gates, Yingjie Ling, Jennifer Mortensen, Fan-Shen Yang, Yu-Shan Lin, Bradley Pentelute
Establishing structure–activity relationships is crucial to understand and optimize the activity of peptide-based inhibitors of protein–protein interactions. Single alanine mutagenesis provides limited information toward this goal. To guide multiple simultaneous peptide modifications with retention of biological activity, we used synthetic combinatorial alanine-scanning libraries—in which each position was varied with either the wild type residue or alanine—with an affinity selection platform to study the mutational tolerance of protein–ligand interactions. Applying this platform to a peptide binder to the oncogenic protein MDM2, several multi-alanine-substituted analogs that retained low nanomolar affinity were discovered, including a 13-mer binder with seven alanine substitutions at non-hotspot positions. These binders served as templates for further modifications, generating cysteine-substituted, perfluoroaryl-stapled peptides with sub-nanomolar affinity and ten-fold improved proteolytic stability. The alanine substitution tolerances for peptide ligands of the 12ca5 antibody and 14-3-3 regulatory protein were also reported, demonstrating the general applicability of this new platform. We envision that deep combinatorial alanine scanning will be a powerful tool for structure–activity optimization of potential peptide therapeutics.


Email Address of Submitting Author


Massachusetts Institute of Technology


United States

ORCID For Submitting Author


Declaration of Conflict of Interest

B.L.P. is a co‐founder of Amide Technologies and Resolute Bio. Both companies focus on the development of protein and peptide therapeutics.